

# Regulatory Survey ION-8139

The data provided on this page is updated by the organisations.

The WMDA makes no representations or express or implied warranties regarding any information on this page.

Use of any information provided on this site does not and is not intended to create a contractual or other relationship.

General	
The information has been reviewed in year :	2024
Organisation name:	Matchis Foundation
Organisation ION:	ION-8139
Country:	The Netherlands
Year the registry started operations:	1988

Products		comment
Do you provide HPC, Marrow?	yes	
Do you provide HPC, Apheresis?	yes	
Do you provide HPC, Cord Blood?	no	Requests for Dutch CBU is forwarded to Sanquin ION-1131
Do you provide MNC, Apheresis?	yes	
Do you provide NC, Whole Blood?	no	

Product quantity		
Data valid for year	2023	
Number of products	National	International
HPC, Marrow products:	9	19
HPC, Apheresis:	28	209
HPC, Cord:	0	0

License	
Organisation is licensed/accredited by the Competent Authority:	yes
Comment:	Tissue establishment license
Name of Competent Authority:	Ministry of Health, Welfare, Sport; Inspected by IGJ
Date of last inspection:	2024/01
Link to website of Competent Authority:	<a href="https://www.government.nl/ministries/ministry-of-health-welfare-and-sport">https://www.government.nl/ministries/ministry-of-health-welfare-and-sport</a>
Can you provide the Legal documentation from the Competent Authority that your organisation is allowed to operate as a registry ?	yes
Is your registry WMDA Certified, WMDA Qualified or WMDA Accredited?	WMDA Accredited
The registry is accredited by any other organisation:	yes
If yes, by which organisation?	ISO27001/NEN7510 certification - data protection

Affiliation	
The registry works with the following number of affiliated donor centres:	0 (Donor centre is a department of the Registry (operating in Leiden and Nijmegen))
The registry audits its donor centres:	yes, internal audits
The registry works with the following number of affiliated collection centres:	2

Ther registry audits its collection centres:	yes
The registry works with the following number of affiliated Cord Blood Banks:	no
The registry audits its Cord Blood Banks:	no
The registry works with the following number of affiliated transplant centres:	10
The registry audits its transplant centres:	no, Transplant centers in the Netherlands are JACIE accredited. Compliance statements to WMDA standards are required
The registry works with the following number of affiliated IDM Testing Laboratories:	3
The registry audits its IDM Testing Laboratories:	no
The registry works with the following number of affiliated HLA/other DNA markers testing laboratories:	3
The registry audits its HLA/other DNA markers testing laboratories:	not standard procedure
The registry would be able to provide a full list of name/addresses of each affiliated and their licence/accreditation status, on request:	yes
The Cord Blood Banks are FACT-NetCord accredited:	
If yes, the following Cord Blood Bank(s) are accredited:	
The registry is able to provide a copy of all the certificates:	yes
Affiliated centres comply with WMDA Standards and applicable national regulations:	yes
The registry has requirements for affiliated centres in addition to WMDA Standards and applicable national regulations:	yes
If yes, what are these requirements?	For the national Transplant centers: License for transplantation with unrelated HPC donor and JACIE accreditation

Donor policy	
All donors are unpaid volunteers:	yes
All donors are informed about donation process and associated risks:	yes
Donors sign a valid informed consent to donate in the presence of a medical doctor/health care personnel/registry staff:	yes
The registry has systems in place to protect and control access to donor/patient records:	yes
The registry maintains donor anonymity:	yes
The registry has detailed donor evaluation and exclusion criteria in place:	yes
The registry has donor evaluation and exclusion criteria that do meet or exceed the WMDA guidelines:	

## IDM

IDM	Tested	Method	Days between test and sampling /workup
ALT/ASTALT/AST ratio, De-Ritis-Quotient	Yes		
ChagasChagas, T. cruzi	On request		
CMV IgGCytomegalovirus (CMV) Antibody testing IgG	Yes	Chemiluminescence Immunosorbent (CLIA) - Architect	
CMV IgMCytomegalovirus (CMV) Antibody testing IgM	On request	Chemiluminescence Immunosorbent (CLIA) - Architect	
CMV TotalCytomegalovirus Total	On request		

EBV IgGEpstein-Barr Virus Antibody testing IgG	On request	Chemiluminescence Immunosorbent (CLIA) - Liaison	
EBV IgMEpstein-Barr Virus Antibody testing IgM	On request	Chemiluminescence Immunosorbent (CLIA) - Liaison	
HAV (NAT)Anti-hepatitis A virus nucleic acid testing	-		
HBV (NAT)Hepatitis B nucleic acid testing	Yes	Quantitative RT-PCR	
HBc AbHepatitis B core antibody testing	Yes	Chemiluminescence Immunosorbent (CLIA)	
HBs AgHepatitis B Surface antigen testing	Yes	Chemiluminescence Immunosorbent (CLIA) - Architect	
HCV (NAT)Hepatitis C nucleic acid testing	Yes	Quantitative RT-PCR - Cobas Taqman	
HCV AbHepatitis C antibody testing	Yes	Chemiluminescence Immunosorbent (CLIA)	
HEV (NAT)Hepatitis E Virus nucleic acid testing	-	Qualitative RT-PCR	
HIV (NAT)Human Immunodeficiency Virus nucleic acid testing	Yes	Quantitative RT-PCR	
HIV-1 AbHuman Immunodeficiency Virus HIV-1 antibody testing	Yes	Chemiluminescence Immunosorbent (CLIA) - Architect - HIV score blot	
HIV-2 AbHuman Immunodeficiency Virus HIV-2 antibody testing	Yes	Chemiluminescence Immunosorbent (CLIA) - Architect - HIV score blot	
HIV p24Human Immunodeficiency Virus p24 antigen testing	On request	Chemiluminescence Immunosorbent (CLIA) - Architect - HIV score blot - HIV duo ultra (VIDAS)	
HTLV-IHuman T-Lymphotropic Virus type I testing	Yes	Chemiluminescence Immunosorbent (CLIA) - Architect - Immunoblot	
HTLV-IIHuman T-Lymphotropic Virus type II testing	Yes	Chemiluminescence Immunosorbent (CLIA) - Architect - Immunoblot	
MalariaMalaria	-	serology or PCR	
HSVHerpes Simplex Virus	-	serology or PCR - Diasorin Liaison XL HSV IgG	
STSSerological tests for syphilis	Yes	Chemiluminescence Immunosorbent (CLIA) - TP Architect - lues blot (INNO-LIA innogenetics ) RPR titratie	
STS FTA-ABSSerological test for syphilis	On request	only at positive STS serology - TP Architect - lues blot Fujireidio	
ToxoplasmosisToxoplasmosis	-	Chemiluminescence Immunosorbent (CLIA)	
VZVVaricella Zoster Virus	-	Chemiluminescence Immunosorbent (CLIA) - Diasorin Liaison XL VZV IgG	
WNV-NATWest Nile Virus nucleic acid testing	On request		
Other tests performed	No		

## Testing

The physical and medical exam at donor workup is performed by a medical doctor:	y es
All donor testing (at workup) for infectious disease is performed in a laboratory certified/licensed by a Competent Authority:	y es
HLA typing for patient specific request is performed in an appropriately accredited laboratory:	y es
Sterility testing is performed on the adult donor product:	y es
Sterility testing is performed on the cord blood product:	
Screening questionnaire to exclude communicable disease:	y es
Screening questionnaire to exclude donors with 'high risk' lifestyles:	y es
Donor reliability identified by a medical doctor:	y es

Donor clearance to donate is confirmed by a medical doctor, following as a minimum the donor exclusion criteria in Annex 1 of <a href="#">EU Directive 2006/17/EC</a> :	y es
The party providing the cell product must exclude donors when:	
<ul style="list-style-type: none"> <li>• They are pregnant;</li> <li>• They are breastfeeding;</li> <li>• There is the potential for transmission of inherited conditions;</li> <li>• There is evidence of any other risk factors for transmissible diseases on the basis of a risk assessment, taking into consideration <i>Donor travel and exposure history and local infectious disease prevalence</i>;</li> <li>• There is presence on the donor's body of physical signs implying a risk of transmissible disease(s);</li> <li>• There is a history of a disease of unknown aetiology;</li> <li>• There is a risk of transmission of diseases caused by prions;</li> <li>• There is systemic infection which is not controlled at the time of donation, including bacterial diseases, systemic viral, fungal or parasitic infections, or significant local infection in the tissues and cells to be donated;</li> <li>• There is history of chronic, systemic autoimmune disease that could have a detrimental effect on the quality of the Cell Product;</li> <li>• There is recent history of vaccination with a live attenuated virus where a risk of transmission is considered to exist;</li> <li>• There is ingestion of, or exposure to, a substance (such as cyanide, lead, mercury, gold) that may be transmitted to recipients in a dose that could endanger their health.</li> </ul>	

## Customs regulations

Are there any customs regulations to follow, or customs paperwork required, to import cell products into the organisation country? If yes, please specify:	No specific custom regulation for import cells out of the Netherlands
Are there any customs regulations to follow, or customs paperwork required, to export cell products from the organisation country? If yes, please specify:	Standard procedure for export: Prior to shipment notification to customs and security; to accompany the product: Collection report, collection details, Transport Audit form, Transplant report, confidentiality policy, if for NMDP: IDM&#39;s, declaration of donor eligibility
Are there any import regulations to follow, or paperwork required, to import cell products into the organisation country? If yes, please specify:	Matchis is licensed to import HPC into the Netherlands and follows strict Matchis safety policies
Are there any export regulations to follow, or paperwork required, to export cell products from the organisation country? If yes, please specify:	

## Reporting of Serious Adverse Events

Please indicate which of the following schemes for reporting Serious Adverse Events relating to either the Donor or the product the Registry participates in:	
- Mandatory National Reporting Scheme	y es
- Voluntary National Reporting Scheme	
- WMDA SEAR/SPEAR Reporting Scheme	y es
The registry will notify the receiving Registry within 24 hours of receiving information relating to any serious adverse event that could be considered to affect the patient receiving the product:	y es

## Quality management

The registry does maintain Standard Operating Procedures for your work:	yes
The registry would be willing to provide these to WMDA or another registry upon request:	yes
The registry would be willing to provide WMDA or another registry, on request, with copies of any packaging the HPC product will arrive in:	yes
Donor records relating to the medical exam and HPC collection process are the following number(s) of year(s) retained:	30